MX369774B - Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. - Google Patents

Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.

Info

Publication number
MX369774B
MX369774B MX2015008454A MX2015008454A MX369774B MX 369774 B MX369774 B MX 369774B MX 2015008454 A MX2015008454 A MX 2015008454A MX 2015008454 A MX2015008454 A MX 2015008454A MX 369774 B MX369774 B MX 369774B
Authority
MX
Mexico
Prior art keywords
pregn
treatment
depressive disorders
depressive
disorders
Prior art date
Application number
MX2015008454A
Other languages
English (en)
Other versions
MX2015008454A (es
Inventor
Monti Louis
Original Assignee
Pherin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherin Pharm Inc filed Critical Pherin Pharm Inc
Publication of MX2015008454A publication Critical patent/MX2015008454A/es
Publication of MX369774B publication Critical patent/MX369774B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La pregn-4-en-20-in-3ß3-ona es útil en el tratamiento de desórdenes depresivos mediante administración nasal.
MX2015008454A 2012-12-28 2013-12-19 Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. MX369774B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261747167P 2012-12-28 2012-12-28
PCT/US2013/076497 WO2014105620A1 (en) 2012-12-28 2013-12-19 Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders

Publications (2)

Publication Number Publication Date
MX2015008454A MX2015008454A (es) 2016-05-16
MX369774B true MX369774B (es) 2019-11-21

Family

ID=49950051

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008454A MX369774B (es) 2012-12-28 2013-12-19 Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.

Country Status (12)

Country Link
US (1) US10322138B2 (es)
EP (1) EP2938346B1 (es)
JP (1) JP6283689B2 (es)
KR (1) KR102209475B1 (es)
CN (1) CN104936600B (es)
AU (1) AU2013371025B2 (es)
CA (1) CA2894686C (es)
DK (1) DK2938346T3 (es)
ES (1) ES2625778T3 (es)
HK (1) HK1210421A1 (es)
MX (1) MX369774B (es)
WO (1) WO2014105620A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020259269B2 (en) * 2019-04-15 2024-03-21 Pherin Pharmaceuticals, Inc. Treatment of migraine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5303703A (en) 1991-10-03 1994-04-19 Pherin Corporation Combined neuroepithelial sample delivery electrode device and methods of using same
ATE255898T1 (de) * 1993-06-15 2003-12-15 Pherin Corp Androstansteroide als neurochemische initiatoren einer veränderung der hypothalamusfunktion beim menschen und verwandte pharmazeutische präparate und verfahren
US6066627A (en) 1994-08-04 2000-05-23 Pherin Corporation Steroids as neurochemical initiators of change in human blood levels of LH
US6057439A (en) * 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US5994333A (en) 1994-08-04 1999-11-30 Pherin Corporation Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6117860A (en) 1994-08-04 2000-09-12 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
US5563131A (en) 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6331534B1 (en) 1994-08-04 2001-12-18 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to alleviate pain
EP0914165B1 (en) * 1996-07-23 2006-10-18 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the vno to alleviate symptoms of pms
US20020123138A1 (en) * 2000-11-30 2002-09-05 Jian Zhang Human VNO receptor (R1)
US20030045514A1 (en) 2001-05-03 2003-03-06 Louis Monti 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors

Also Published As

Publication number Publication date
AU2013371025A1 (en) 2015-07-09
CN104936600A (zh) 2015-09-23
AU2013371025B2 (en) 2018-01-18
KR20150100884A (ko) 2015-09-02
ES2625778T3 (es) 2017-07-20
JP6283689B2 (ja) 2018-02-21
JP2016504361A (ja) 2016-02-12
US10322138B2 (en) 2019-06-18
EP2938346A1 (en) 2015-11-04
US20140187524A1 (en) 2014-07-03
CA2894686C (en) 2021-05-04
HK1210421A1 (en) 2016-04-22
CN104936600B (zh) 2018-08-03
DK2938346T3 (en) 2017-06-12
KR102209475B1 (ko) 2021-01-28
CA2894686A1 (en) 2014-07-03
MX2015008454A (es) 2016-05-16
EP2938346B1 (en) 2017-04-05
WO2014105620A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
IL269852B (en) Combined treatments and uses for the treatment of demyelination disorders
IL266159A (en) Treatment of circadian rhythm disorders
IN2015DN01156A (es)
HK1215375A1 (zh) 阿克曼氏菌用於治療代謝病症的用途
PH12015500525A1 (en) Formulations of enzalutamide
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
IN2014DN09434A (es)
EP2827869A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
IL233714A0 (en) Treatment of diseases related to the circadian rhythm
PL2704704T3 (pl) Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
MY181828A (en) Bicyclically substituted uracils and the use therapy
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
PL2919796T3 (pl) Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
HK1218373A1 (zh) 用於治療年齡相關失調的重組膠原蛋白 的給予
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders
GB201303721D0 (en) Compositions for treatment of sleep disorders

Legal Events

Date Code Title Description
FG Grant or registration